|
|
Blood, 15 April 2004, Vol. 103, No. 8, pp. 2939-2941.
Prepublished online as a Blood First Edition Paper on December 24, 2003; DOI 10.1182/blood-2003-10-3620.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome
Amy D. Klion,
Melissa A. Law,
Pierre Noel,
Yae-Jean Kim,
Thomas P. Haverty, and
Thomas B. Nutman
From the Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); Department of Laboratory Medicine, Warren Grant Magnusson Clinical Center, NIH, Bethesda, MD; and Schering-Plough Research Institute (SPRI), Kenilworth, NJ.
Four patients with hypereosinophilic syndrome (HES) refractory to or intolerant of treatment with conventional therapy were treated with a single 1 mg/kg dose of SCH55700 SCH55700was extremely well tolerated. Two of the 4 patients responded with a fall in eosinophil counts to within the normal range within 48 hours of receiving the drug, accompanied by marked improvement in clinical signs and symptoms. Response was not predicted by serum interleukin-5 (IL-5) levels or presence of the FIP1L1/PDGFRA mutation. Eosinophil counts remained suppressed for up to 12 weeks after treatment; however, exacerbation of symptoms and eosinophilia above baseline levels occurred as drug levels waned. Reinstitution of treatment with monthly SCH55700led to decreased eosinophilia and symptomatic improvement, albeit to a lesser degree than that seen after the initial dose. These data suggest that anti–IL-5 therapy may be useful in the treatment of HES irrespective of the underlying etiology, although the observed rebound eosinophilia and attenuation of response require further study. (Blood. 2004;103:2939-2941)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Nair, M. M.M. Pizzichini, M. Kjarsgaard, M. D. Inman, A. Efthimiadis, E. Pizzichini, F. E. Hargreave, and P. M. O'Byrne
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
N. Engl. J. Med.,
March 5, 2009;
360(10):
985 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Rothenberg, A. D. Klion, F. E. Roufosse, J. E. Kahn, P. F. Weller, H.-U. Simon, L. B. Schwartz, L. J. Rosenwasser, J. Ring, E. F. Griffin, et al.
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
N. Engl. J. Med.,
March 20, 2008;
358(12):
1215 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. O'Byrne
The Demise of Anti IL-5 for Asthma, or Not
Am. J. Respir. Crit. Care Med.,
December 1, 2007;
176(11):
1059 - 1060.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Frankel, S. D. Groshong, and D. A. Lynch
Invited Commentary
RadioGraphics,
May 1, 2007;
27(3):
637 - 639.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamada, M. E. Rothenberg, A. W. Lee, H. S. Akei, E. B. Brandt, D. A. Williams, and J. A. Cancelas
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease
Blood,
May 15, 2006;
107(10):
4071 - 4079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc.,
April 1, 2006;
81(4):
553 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Blood Eosinophilia: A New Paradigm in Disease Classification, Diagnosis, and Treatment
Mayo Clin. Proc.,
January 1, 2005;
80(1):
75 - 83.
[Abstract]
[PDF]
|
|
|
|
|
